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Summary
Incubation of thehumanT cell lymphotropic virus (HTLV)-IIIB andHTLV-RF strains ofhuman
immunodeficiency virus type 1(HIV1) with normal seronegative human serum under conditions
that allow complement activation resulted in enhancement of infection of the MT2 human T
cell line cultured in the presence of low amounts of virus. Infection ofMT2 cells was assessed
by measuring reverse transcriptase activity in supernatants at day 9 ofculture. Complement activation
by viral suspensions occurred through the alternative pathway. Opsonization ofHTLVRF viral
particles with complement was sufficient to allow a productive infection to occur in cells exposed
to suboptimal amounts of virus. Infection of MT2 cells with suboptimal amounts of serum-
opsonized HIV-1 was suppressed by blocking the C3dg receptor (CR2, CD21) on MT2 cells
with monoclonal anti-CR2 antibody and rabbit F(ab')2 anti-mouse immunoglobulin antibodies .
Blocking ofthe gp120-binding site onCD4 under similar experimental conditions had no inhibitory
effect on infection ofMT2 cells with opsonized virus . Opsonization ofHIV-1 with seronegative
serum also resulted in a CR2-mediated enhancement of the infection of normal peripheral blood
mononuclear cells and T lymphocytes . These results indicate that complement in the absence
of antibody may enhance infection of C3 receptor-bearing T cells with HIV1, and that the
interaction of opsonized virus with the CR2 receptor may result by itself in the infection of
target T cells in a CD4- and antibody-independent fashion .
T
he CD4 molecule functions as a high affinity cellular
receptor for the gp120 envelope protein ofHIV-1 (1-3) .
The binding site of gp120 on CD4 has been mapped using
mAbs directed against human CD4 and site-directed muta-
genesis of the CD4 gene (4) . CD4 serves as the primary
receptor for HIV on T lymphocytes and may be important
for viral entry into CD4+ monocyte/macrophages (5-8) .
However, a number of phenotypically and/or genomically
CD4 - human cells may be infected with HIV in vitro
(9-18), implicating that alternative pathways for viral entry
should be considered .
A role for lymphocyte function-associated antigen type
1 (LFA-1)' (CD11a/CD18) in the fusion process of HIV
with target cell membranes has recently been suggested (19,
20) . There is also evidence for a role of anti-HIV antibodies
and Fc receptors on monocyte/macrophages in enhancing viral
1 Abbreviations used in this paper . HTLV, human T cell lymphotropic virus;
IU, infectious units ; LFA-1, lymphocyte function-associated antigen type
1;MOI, multiplicity ofinfection;NHS, normal humanserum ; RT, reverse
transcriptase.
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binding and infection (21), and for an enhancing role of anti-
body and complement in the infection of the MT2 T cell
line (22) and of EBVtransformed human B cells (23, 24) .
Retroviruses activate human complement (25-29) . Intact
HIV (30), recombinant gp160 of HIV (Thieblemont, N .,
N . Haeffner-Cavaillon, L . Weiss, F. Maillet, and M . D.
Kazatchkine, manuscript submitted for publication), andHIV
infected cells (31) activate complement in wholehuman serum
resulting in cleavage ofC3 and deposition ofC3 fragments
on the viral surface . Surface-fixed fragments of C3 may in-
teract with specific C3 receptors on a variety ofcells, including
monocyte/macrophages, B cells, and T cells (32) . 10% of
normal peripheral blood T lymphocytes express the Cab
receptor, CR1 (CD35) (33, 34) ; -40% of T cells express
low amounts of CR2 (C3dg/EBV receptor, CD21) (35) .
The present study demonstrates that the infection of the
CR2-positive humanT cell line MT2 withHIV-1 in the pres-
ence of low amounts of virus is greatly enhancedwhenHIV
is pre-opsonized with seronegative human serum . Infection
of MT2 cells with serum-opsonized virus occurred in an
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HIV with seronegative serum also enhanced infection of
normal humanPBMC andT lymphocytes. The enhancing
effect ofcomplement was mediated by the interaction of op-
sonized virus with the CR2 receptor on target T cells .
Materials and Methods
Sera andAntibodies.
￿
Normal human serum(NHS)was obtained
from three healthy individuals seronegative for HIV-1 and HIV2 .
C2-deficient serumwasfrom a homozygous-deficient patient . Factor
B-depleted human serumandnormal guinea pig serumwere pur-
chased from Sigma Chemical Co ., St . Louis, MO .
mAbOKT4Aof theIgG2a isotype (Ortho Diagnostic Systems,
Raritan, NJ) directed against theHIV binding site-related epitope
of human CD4, IgG2a mAb BL4 directed against human CD4
(kindly provided byJ . Brochier, Montpellier, France), IgG2a mAb
HB5 directed against human CR2 (CD21) (Becton Dickinson&
Co ., Mountain View, CA), and rabbit F(ab')2 antibodies against
mouse Ig (Cappel Laboratories, Cochranville, PA) were obtained
as indicated .
Target Cells. The MT2 cell line is highly sensitive to the
cytopathic effect ofHIV-1 (36) . MT2 cells express CD4 and CR2
(CD21) antigens (37) . The cell line was maintained inRPMI 1640
(Gibco-BRL, Cergy, France) supplemented with 10% heat-
inactivated FCS (Biosys, Compiegne, France) and antibiotics . For
experiments usingPBMC as targets cells for infection, PBMC were
isolated from whole blood of HIV1-seronegative individuals on
Ficoll-Hypaque . Purified T cell lymphotropic (CD2' cells) were
obtained from PBMC by rosetting with 2-AETtreated sheep
erythrocytes. The cells contained >95% CD3' cells and <1%
CD20' cells. Cells were stimulated with PHA (9 P.g/ml) (Well-
come Laboratories, Beckenham, UK) for3 dand then cultured in
fresh culture medium containing rIL2 (20 U/ml) (Boehringer,
Mannheim, FRG) .
Sources of Viruses. The human T cell lymphotropic virus
(HTLV)-IIIB and HTLVRF isolates of HIV-1 were cultivated in
H9 cells. Viruswas obtained from supernatants ofde novo infected
cells, clarified from cells by low-speed centrifugation at 400g for
10 min, passed through a 0.45-Am filter membrane, and stored at
-80°C until use. In coculture experiments, the sources of virus
were PBMC from two HIV-1-infected patients.
Viral Titration.
￿
To determine the infectious titer of viral sus-
pensions, H9 cells (105 cells in 0.2 ml of culture medium) were
infected with 0.1 ml of serial viral dilutions; 300 Al of culture
medium was added daily to the cultures as described in reference
38 . After 10 d of culture, the highest viral dilution that yielded
reverse transcriptase (RT) activity (39) that was at least 20-fold
above background activity was defined as the infectious titer of
the viral suspension . The titers ofHTLVIIIB and HTLVRF stock
suspensions were 105 and 106 infectious units (IU)/ml, respectively .
Multiplicity ofinfection (MOI)defined the number of IU per cell
used for infection .
Infection ofMT2 Cells with HIV-1.
￿
Infection ofMT2 cells was
performed in 24-well plates. HIV-1 at appropriate dilutions in cul-
ture medium (500 ul final volume) was incubated in the presence
or absence of 25 pl of normal human seronegative serum for 1 h
at 37°C. MT2 cells (3 x 105 cells in 1.5 ml of culture medium)
were then added to the mixture and incubated ovemight in 5%
C0 2 at 37°C. Cells were washed once with Hank's balanced so-
lution (Gibco-BRL), resuspended in 2.0 ml of fresh culture medium,
and cultured in another 24-well plate in the presence of5% C02
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at 37°C. Cultures were examined daily under microscope for the
cytopathic effect ofHIV At day9ofculture, the supernatants were
collected and tested for RT activity.
Results
Complement-mediatedEnhancementofInfection ofMT2Cells
with HIV-1. The enhancing effect of seronegative human
serum on infection ofMT2 cells with theHTLVIII-RF and
HTLVIIIB strains of HIV -1 is shown in Fig . 1 . In the ex-
periments depicted, viral particles were preincubated either
with a fixed amount of serum or with culture medium for
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Figure 1.
￿
Enhancement by seronegative human serum of infection of
MT2 cells withHIV1 . MT2 cells were infected with increasing amounts
of the HTLVIIIB (A) or HTLVRF (B) strain of HIV -1 that had been
preincubated with seronegative human serum (*) (25 pl in 500 ul of
viral suspension) or with culture medium (O) for 1 h at 37°C . RT ac-
tivity was assessed on day9 of culture. MOI equals the number of viral
infectious units per cell .
Complement Mediates Human Immunodeficiency Virus Infection
7
10-5 10 -4 10 -3 10-2
Viral input (M01)
10-4
Viral input (MOI)106 -
E
105 -
104
NHS (pl)
Figure 2.
￿
Enhancement by seronegative human serum HIV infection
ofMT2 cells. A fixed concentration ofHTLVIIIB (MOI 10- 3) was prein-
cubated with increasing amounts ofserum from three seronegative healthy
individuals (NHS) before using the virus for infection ofMT2 cells. RT
activity was assessed on day 9 of culture.
1 h at 37°C before the virus was used to infect MT2 cells.
Infection was assessed by measuringRT activity of the cul-
ture supernatants at day9oftheculture. Theenhancing effect
of serum was observed at low inputs of virus (MOI <10-3);
it was not seen at high viral inputs (MOI >10-2). Maximal
enhancement ofHIVinfection that was achieved was 10-fold
with the HTLVIIIB strain used at MOI of 10 -3 and 50-fold
with the HTLVRF strain at MOI of 10-4 . Cytopathic
changes with the appearance ofmultinuclear giant cells due
to cell fusion were observed as early as day 5 in cultures of
cells infected with serum-opsonized virus . The changes oc-
curred at day7or later in cultures ofcells infected with nonop-
sonized virus . Fig. 2 shows that the enhancing effect of normal
seronegative serum on HIV infectionofMT2 cells was dose
dependent .
To demonstrate that the serum-mediated enhancing effect
that we observed was dependent on complement activation,
experiments similar to those depicted in Fig . 1 were performed
using EDTA-chelated serum or sera deficient in classical
pathway or in alternative pathway proteins. Table 1 shows
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Table 1 .
￿
Alternative Complement Pathway Dependency of the
Enhancing Effect ofHIV-seronegative Serum on Infection ofMT2
Cells with HIV-1
Source of serum
Culture medium
NHS
NHS-EDTA
C2-deficient serum
Factor B-depleted serum
RT activity
cpm x 10-5/ml
0.18
7.6
0.26
7.8
0.16
MT2 cells were infected with a fixed amount of the HTLV-RF strain
of HIV-1 (MOI 10 -4 ) that had been preincubated with serum (25 Al)
or with culture medium for 1 h at 37°C. RT activity was assessed at
day9 of the culture . NHS : serum from a healthy HIV-seronegative in-
dividual ; NHS-EDTA : NHS that had been dialyzed against 10 rum
EDTA ; C2-deficient serum: serum from a homozygous C2 individual;
factor B-depleted serum : NHS depleted of factor B of the alternative
pathway .
that chelation of Cat' and Mgt+ with EDTA or the use of
factor 13--depleted serum abolished the enhancing effect of
serum on HIV infection of MT2 cells . C2-deficient serum
exhibited a similar enhancing capacity as that ofnormal human
serum, indicating that enhancement ofinfection was depen-
dent on complement activation through the alternative
pathway. Heat treatment ofNHS (30 min at56°C) also sup-
pressed theenhancing effect of serum; normal guinea pigserum
had no enhancing activity (data not shown) .
Complement-opsonized HIV-1 InfectsMT2 Cells through In-
teraction with CR2 in a CD4-independent Fashion . Staining
with anti-C3 receptor mAbs demonstrated that MT2 cells
only express the C3dg receptor, CR2 (CD21), and do not
express CR1(CD35) andCR3 (CD11b/CD18) complement
receptor antigens (datanot shown) . Therole ofCR2 in medi-
Figure 3 .
￿
CR2 mediates infection ofMT2 cells with
complement-opsonized HIV-1 . MT2 cells were infected
with theHTLVRF strain ofHIV -1 (MOI 10-4) that had
been preincubated with 25 ul of normal seronegative
human serum as depicted in Fig. 1. Before infection, MT2
cells wereincubated with saturating amounts ofanti-CR2
antibody HB5 followed or not by rabbit F(2V)2 anti-
mouse Ig antibodies (RAM) . RT activity was assessed
at day9 ofculture. Nonopsonized virus : cells infected with
virus in the absence of opsonization with serum ; NHS-
opsonized virus: cells infected with virus that had been
preincubated with seronegative human serum ; NHS-
opsonized virus + HB5 : cells preincubated with anti-CR2
mAbHB5and infectedwithcomplement-opsonized virus;
NHS-opsonized virus + HB5 + RAM: cells preincubated
with anti-CR2 mAb HB5 crosslinked with RAM and
infected with complement-opsonized virus ; NHS-opson-
ized virus + NaAz + RAM: cells preincubated with
NaAz (0.1%, i.e., at an equivalent concentration to that
present in the HB5 mAb solution) and RAM, and in-
fected with complement-opsonized virus.ating the infection of MT2 cells with virus that had been
opsonized with complement was demonstrated in the experi-
ments depicted in Fig. 3 . MT2 cells were cultured in thepres-
ence of suboptimal amounts of virus of the RF strain (MOI
10-4) that had been pre-opsonized with seronegative serum .
At day 9 of culture, infection with opsonized viral particles
resulted in significant RT activity, whereas background levels
ofRT activity were observed in cultures infected with nonop-
sonized virus . Blocking ofCR2 onMT2 cells with saturating
amounts of the anti-CR2 mAb HB5 that had been cross-
linked with F(ab')2 anti-mouse Ig rabbit antibodies resulted
in a backgroundRT activity similar to that observed in con-
trol cultures infected with nonopsonized virus. The condi-
tions used for blocking CR2 on MT2 cells were those that
totally suppressed rosette formation of the CR2-expressing
T cell lineHPBALL with Cad-coated sheep erythrocytes (data
not shown) . No capping of CR2 antigen was observed on
MT2 cells incubated with anti-CR2 and rabbit anti-mouse
Ig antibodies (data not shown) . Preincubation of MT2 cells
withmAb HB5 without rabbit anti-mouse Ig antibodies sup-
pressed RT activity of cells infected with complement-
opsonized virus by -30%.
Blocking experiments using anti-CD4 antibodies resulted
in no inhibition of RT activity in cultures ofMT2 cells in-
fected with complement-opsonized virus (Fig . 4) . The ex-
periments were performed with saturating concentrations of
mAb OKT4A, which binds to the gp120-binding site epi-
tope on CD4, or with mAb BL4, which recognizes another
epitope on CD4 independent of the binding site for gp120 .
Both mAbs OKT4A and BL4 were crosslinked with rabbit
anti-mouse Ig antibodies . OKT4A and rabbit anti-mouse
Ig F(ab')2 were used in amounts that inhibited RT activity
in cultures ofMT2 cells infected with optimal amounts of
virus (data not shown) . Thus, infection of MT2 cells with
preopsonized virus occurred through interaction with CR2,
independently of the CD4 molecule .
Complement-dependent Infection of PBMC with HIV-1 .
PBMC from HIV-1-infected donors (106 cells/well) were
cocultured with an equalnumber ofPHAstimulatedPBMC
from an HIVseronegative individual in the presence or ab-
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Table 2.
￿
Enhancing Effect ofHIV-seronegative Serum on Infection
of Normal Human PBMC with HIV-1
Mediates Human Immunodeficiency Virus Infection
RT activity
HIV opsonized HIV opsonized with
￿
Relative
MOI
￿
with NHS
￿
heat-treated NHS
￿
enhancement
cpm x 10- '/ml
2.5 x 10 -4
￿
1.7
￿
0.8
￿
2.1
2.5 x 10 -5
￿
4 .1
￿
0.5
￿
8.2
2.5 x 10 -6
￿
2 .6
￿
0 .4
￿
6.5
PBMC from a healthy seronegative donor were cultured with HTLV-
RF that hadbeen preincubated withNHS or heat-treatedNHS and then
stimulated withPHA (9 Rg/ml) for 3 d before assessment ofRT activi-
ty in culture supernatants .
sence of normal human seronegative serum (100 /Al in 2.0
ml of final culture volume) for 18 d . Human serum was kept
throughout the culture by adding fresh serum twice aweek
at the timewhen the culturemedium was changed . The pres-
ence of serum resulted in up to 4- and 10-fold enhancement
in RT activity in supernatants of coculture with cells from
two HIVinfected donors (Fig. 5) .
In another series of experiments, PHA-stimulated PBMC
or purified peripheral blood T cells from four seronegative
donors (106 cells/well) were cultured with low amounts
(MOI 2.5 x 10 -5 ) of HTLVRF that had been pre-
opsonized or not with normal human seronegative serum .
Depending on the donor, a 1.7-2.7-fold enhancement ofRT
activity was observed between days 3 and 9 in cultures of
PBMC and ofT cells infected with serum-opsonized virus
as compared with cultures of cells treated with heat-inactivated
serum . The enhancing effect of serum was abrogated if cells
were pretreated with anti-CR2 mAb HB5 and F(ab')2 anti-
mouse rabbit antibodies (data not shown) . Since PHA stim-
ulation downregulates the expression of CR2 on human T
Figure 4.
￿
Lack of effect of anti-CD4 antibodies on in-
fection ofMT2 cells with complement-opsonized virus .
MT2 cells wereinfectedwith theHTLVRF strain ofHIV -1
(MOI 10-4) that had been preincubated with seronega-
tive human serum as depicted in Fig. 1. Before infection,
MT2 cellswereincubatedwith saturating amounts ofanti-
CD4 mAb OKT4A or BL4 followed by rabbit F(ab')2
anti-mouse Ig antibodies (RAM). RT activity was as-
sessed at day 9 of culture. Nonopsonized virus : cells in-
fected with virus in the absence of opsonization with
serum; NHS-opsonized virus : cells infected with virus that
had been preincubated with seronegative human serum ;
NHS-opsonized virus + OKT4A + RAM : cells prein-
cubated with mAb OKT4A crosslinked withRAM and
infected with complement-opsonized virus; NHS-
opsonized virus + BL4 + RAM : cellspreincubatedwith
mAb BL4 crosslinked with RAM and infected with
complement-opsonized virus.4
2
3-
B
cells, PBMC from one donor were infected with serum-
opsonized or with nonopsonizedHTLVRF, washed, and then
cultured in the presence ofPHA for 3 d . As shown in Table
2, pretreatment of HIV with serum resulted in a 2.1-8.2-
fold enhancement of RT activity, depending on the input
ofvirus . Maximal enhancement ofHIV infection was achieved
at suboptimal amounts of HTLVRF (MOI 2.5 x 10-5 ) .
Discussion
8
￿
12
￿
16
Time (days)
The present study demonstrates that complement enhances
infection of the human T cell line MT2 and of peripheral
blood T lymphocytes with HIV1, and may mediate alone
the infection of cells with suboptimal amounts of virus . In-
fection ofthe cells with complement-opsonized virus occurred
through an interaction ofopsonized particles with theC3dg
(CR2) receptor on targetT cells in an antibody-independent
process.
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Figure 5 .
￿
Kinetics of enhancement by seronegative
human serum ofHIV infection ofPBMC cocultured with
infectedPBMC. PHAstimulatedPBMC from a seronega-
tive individual were cocultured with PBMC from two
HIV-1-infected patients in the presence (*) or absence
(0) of normal human seronegative serum.
Preincubation of viral particles with normal seronegative
human serum under conditions that allow complement acti-
vation resulted in enhanced infection ofMT2 cells exposed
to low amounts ofvirus. Enhancement ofinfection was greater
when using the HTLVRF strain of HIV1, which is more
effective in infecting MT2 cells than the HTLVIIIB strain .
No enhancement ofinfection had been observed by Robinson
et al . (37) using the same target cells and strain of virus in
the absence of anti-HIV antibodies ; however, the relatively
high amounts ofvirus that these authors usedmay have been
above the threshold at which enhancement may be seen .
Antibody-independent enhancement ofHIV infection ofMT2
cells has been observed when using desialylated virus (40) .
The latter phenomenon could be interpreted as being depen-
dent on an increased deposition ofC3 on the virus, through
enhanced alternative complement pathway activation by
desialylated viral particles (41) . There is evidence that intact
HIV-1 (30), the glycosylated recombinant gp160 envelope pro-tein (Thieblemont N ., N . Haeffner-Cavaillon, L . Weiss, F.
Maillet, andM . D. Kazatchkine, manuscript submitted for
publication), and HIVinfected cells (31) activate human com-
plement in whole serum with subsequent binding ofC3 frag-
ments to the virus . Whereas infected cells activate the alter-
native pathway, intact HIV and the gp160 protein activate
the classical pathway in an antibody-independent fashion . Our
observations with C2 and with factor B-deficient serum in-
dicate that complement activation by the infectious viral sus-
pensions that we used occurred through the alternative
pathway.
Fragments ofC3 that becomebound to complement acti-
vators may interact with at least three types of complement
receptors for surface-fixed fragments of C3, termed CR1
(CD35), CR2 (CD21), andCK3 (CD11b, CD18) (32) . The
MT2 cell line only expresses theCR2 receptor that preferen-
tially recognizes theC3dg fragment of C3, butmay also bind
Cab and iC3b . Blocking ofCR2 by crosslinking the receptor
with anti-CR2 mAb followed by a second anti-mouse Ig
antibody totally suppressed RT activity in cultures ofMT2
cells infected with HIV-1 that had been pre-opsonized with
complement in the absence of antibody. We crosslinked the
receptor on the cells because anti-CR2 mAb HB5 is not
directed against the C3dg binding site on the CR2 mole-
cule . The interaction of opsonized virus with CR2 was
sufficient to allow penetration of the virus in MT2 cells and
result in productive infection at day 9 of the culture, since
blocking ofCD4 with crosslinked anti-CD4 mAb OKT4A
had no inhibitory effect on infection ofthe cells . Thus, serum-
opsonized HIV-1 may penetrate into T cells through CR2
in an antibody- and CD4-independent fashion.
The role ofCR2 in allowing infection ofMT2 cells with
opsonized HIV-1 was shown under experimental conditions
using suboptimal amounts of virus and assessing RT levels
at day 9 ofculture o£infected cells. It is possible that at higher
concentrations of virus or if using a longer culture period,
an additive or synergistic contribution of CR2 and CD4 in
determining infection would have been observed . Such a syn-
ergistic effect of CR2 and CD4 has recently been reported
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